Discover this groundbreaking webinar delving into the strategic approaches of bispecific antibody (BsAb) design, production and purification. BsAbs have become increasingly of interest by enabling new therapeutic applications for a variety of indications, including cancer, chronic inflammatory diseases, autoimmunity, neurodegeneration, bleeding disorders and infections. Currently, there are 12 bispecific antibodies approved worldwide.
Natural antibodies are monospecific, while BsAbs recognize two different epitopes or antigens. This makes BsAbs hold great therapeutic promise for many diseases by linking an effector to a target cell, acting as ligands to two receptors or other mechanisms. However, the translation of these concepts into treatments is challenging. Without proper engineering, the side products from the light chain mispairing, heavy chain mispairing and BsAb fragments could lead to low purity, inability of repetition and toxicity.
To solve the technical problems, advanced design strategies have been investigated, such as Knobs-into-holes, CrossMab technology, Duobody and common light chain. These technologies have greatly improved the development of bispecific antibodies, with many entities employing similar design approaches to develop their BsAb therapeutics.
Do BsAb designs always work well as reported? What considerations should be taken for BsAb design?
GenScript has production experience on thousands of BsAbs including about 80 BsAb formats and know well how the design affects the production.
This webinar will focus on various strategies for BsAb design, the side products and how to get high purity BsAbs with different purification columns.
Join this webinar to gain insights into the diverse applications, design considerations and production strategies of bispecific antibodies.
Xiaoyu Chen, PhD, Protein Senior Scientist, GenScript
Dr. Xiaoyu Chen obtained her Science PhD from the Center of Excellence in Molecular Cell Science, Chinese Academy of Sciences. Her main project involves investigating the structure and function of G protein-coupled receptors, leading the analysis of the first alpha-2C adrenergic receptor protein structure. The research finding was published in Cell Reports.
After joining GenScript, Dr. Xiaoyu Chen has overseen the establishment of the bispecific antibody expression platform with her extensive production experience.
Who Should Attend?
This webinar will appeal to academic and industry professionals in the following areas:
- Antibody drug discovery
- Antibody discovery
- Antibody production
- Antibody therapeutics
What You Will Learn
Attendees will gain insights into:
- Structural design difficulties and research progress of bispecific antibodies
- Key considerations of bispecific antibody structural design and analysis of general design strategies
- Production strategies and by-product purification plans for bispecific antibodies with different structures
GenScript is the leading contract research organization in the world providing gene, peptide, protein, CRISPR, and antibody. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science research, translational biomedical research, and early stage pharmaceutical development. The company is recognized as having built a best-in-class capacity and capability for biological research services, encompassing gene synthesis, peptide synthesis, custom antibody and protein engineering, and in vitro and in vivo pharmacology – all with the goal to Make Research Easy.